Previous vaccination lowers the risk of shingles among older patients undergoing chemotherapy by 42 percent
Kaiser Permanente Study Finds Shingles Vaccine Remains Effective After Chemotherapy
PASADENA, Calif., Aug. 5, 2014 /PRNewswire/ -- The herpes zoster vaccine continues to be effective in protecting older adults against shingles, even after they undergo chemotherapy, according to a Kaiser Permanente study published today in the journal Clinical Infectious Diseases.
Researchers examined the electronic health records of more than 21,000 Kaiser Permanente patients in Southern California who were 60 years of age and older and received chemotherapy between January 2007 and December 2012.
Researchers found that those patients who were previously vaccinated with zoster vaccine were 42 percent less likely to develop shingles following chemotherapy. In addition, no vaccinated patients underwent hospitalization for shingles, while six unvaccinated patients were hospitalized with the disease, according to the study.
"The zoster vaccine has been shown to be safe and effective in elderly adults with healthy immune systems but until now, there has been a lack of data on whether the vaccine remains safe and effective for individuals who might have compromised immune systems resulting from treatments like chemotherapy," said study lead author Hung Fu Tseng, PhD, MPH, of the Kaiser Permanente Southern California Department of Research & Evaluation. "Our study demonstrates that older patients who had previously been vaccinated against shingles have a lower chance of developing this painful and often debilitating disease after chemotherapy."
Shingles is caused by the varicella zoster virus and can affect anyone who has had chickenpox. Symptoms of shingles include a painful rash and blisters that develop on one side of the face or body as well as fever, headache and chills. According to the Centers for Disease Control and Prevention, before the zoster vaccine was available, almost one out of every three people in the United States would develop shingles at some point in their lifetime, which translated into more than 1 million cases of shingles expected each year in the U.S.
The risk of developing shingles also increases among those receiving treatments that weaken the immune system, such as chemotherapy for cancers. The lifetime risk of developing cancer is nearly 40 percent among 60 year-old adults, according to the National Cancer Institute. The CDC recommends that people aged 60 years and older get one dose of the zoster vaccine as this is the only way to reduce the risk of developing shingles and prevent long-term complications.
"Age is associated with increased risk of cancers and other medical conditions that may require immunocompromising treatments such as chemotherapy," said Tseng. "It is important that elderly patients get vaccinated when they are relatively healthy, or before starting immunocompromising treatments, because the vaccine isn't advised for those who have weakened immune systems."
Kaiser Permanente can conduct transformational health research in part because it has the largest private patient-centered electronic health record in the world. The organization's electronic health record, Kaiser Permanente HealthConnect®, securely connects approximately 9.3 million patients to 17,000 physicians in 618 medical offices and 38 hospitals. It also connects Kaiser Permanente's research scientists to one of the most extensive collections of longitudinal medical data available, facilitating studies and important medical discoveries that shape the future of health and care delivery for patients and the medical community.
Other authors of the study include: Sara Tartof, PhD, Yi Luo, MS, Lina S. Sy, MPH, Rulin C. Hechter, MD, PhD, and Steven J. Jacobsen, MD, PhD, of the Kaiser Permanente Southern California Department of Research & Evaluation; and Rafael Harpaz, MD, MS, of the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention.
About the Kaiser Permanente Southern California Department of Research & Evaluation The Department of Research & Evaluation conducts high-quality, innovative research into disease etiology, prevention, treatment and care delivery. Investigators conduct epidemiology, health sciences and behavioral research as well as clinical trials. Areas of interest include diabetes and obesity, cancer, HIV/AIDS, cardiovascular disease, aging and cognition, pregnancy outcomes, women's and children's health, quality and safety, and pharmacoepidemiology. Located in Pasadena, California, the department focuses on translating research to practice quickly to benefit the health and lives of Kaiser Permanente Southern California members and the general population. Visit kp.org/research .
About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve approximately 9.3 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.
For more information: Vincent Staupe, [email protected] , 415.318.4386
Sandra Hernandez-Millett, [email protected] , 626.405.5384
Logo - http://photos.prnewswire.com/prnh/20130718/SF49717LOGO
SOURCE Kaiser Permanente
Copyright (C) 2014 PR Newswire. All rights reserved